Clinical Trials Directory

Trials / Terminated

TerminatedNCT00406822

OculusGen-Glaucoma Historical Control Study in Taiwan

Study of the Safety and Effectiveness of the OculusGen Collagen Matrix Implant as an Aid in Glaucoma Surgery

Status
Terminated
Phase
Phase 3
Study type
Interventional
Enrollment
48 (estimated)
Sponsor
Pro Top & Mediking Company Limited · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine whether the OculusGen Collagen Matrix are effective and safe to implant as an aid of glaucoma surgery.

Detailed description

OculusGen® Collagen Matrix is a porous, scaffold matrix. It is to be implanted on the top of the scleral flap and beneath the conjunctiva and Tenon's capsule at the end of trabeculectomy. The pores in the scaffold matrix range from 20 to 200µm, a size that is suitable for fibroblasts to grow randomly, through the body of the matrix without causing scarring. The space occupied by the collagen matrix scaffold creates room for the development of a filtration bleb. Immediately after implantation, the collagen matrix is absorbed with the aqueous humor that bring a certain pressure press on the top of scleral flap which makes the dynamic balance for the aqueous system to keep the IOP in the right side. The collagen matrix is bio-degraded within 90 days and will leave a physiologic space for the filtration bleb to facilitate control of intraocular pressure (IOP).

Conditions

Interventions

TypeNameDescription
DEVICEOculusGen Biodegradable Collagen Matrix Implant

Timeline

Start date
2006-12-01
First posted
2006-12-04
Last updated
2008-05-05

Locations

1 site across 1 country: Taiwan

Source: ClinicalTrials.gov record NCT00406822. Inclusion in this directory is not an endorsement.